文献速递糖尿病

评估胰岛素类型(超速效与速效胰岛素)和运动时机对1型糖尿病患者餐后运动诱发低血糖风险的影响:一项随机对照试验

Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-07-29

该四向交叉随机试验纳入40例使用每日多次注射的1型糖尿病患者,比较早餐后60分钟与120分钟运动及门冬胰岛素与超速效门冬胰岛素对运动诱发低血糖风险的影响。结果显示EX60min较EX120min运动前高血糖时间更短、运动期间血糖降幅更小;超速效门冬胰岛素较门冬胰岛素运动期间血糖降幅更小,且运动后低血糖事件更少。

要点

  • EX60min较EX120min运动前高血糖时间更短,运动期间血糖降幅更小。
  • 超速效门冬胰岛素较门冬胰岛素运动期间血糖降幅更小。
  • 超速效门冬胰岛素运动后低血糖事件更少(0% vs 38%)。

核心结论

  • EX60min减弱了早餐后运动前血糖升高,并与运动期间更小的血糖降幅相关。
  • 超速效门冬胰岛素导致运动期间更小的血糖降幅,可能与运动后低血糖减少相关。

研究设计与样本

  • 四向交叉随机试验,纳入40例使用每日多次注射的1型糖尿病患者(平均HbA1c 56 mmol/mol [7.4%]),招募自蒙特利尔临床研究所。
  • 参与者进行60分钟骑行(60% V˙O2peak),在早餐后60分钟(EX60min)或120分钟(EX120min)运动,使用50%的常规胰岛素剂量(门冬胰岛素或超速效门冬胰岛素)。
  • 纳入标准包括年龄≥18岁、临床诊断1型糖尿病至少1年、HbA1c≤80 mmol/mol(9.5%);采用序贯编号不透明密封信封分配,参与者对分组设盲。
  • 主要结局为运动开始至最低点之间的血糖变化。

主要发现

  • 运动开始前,EX60min vs EX120min的高血糖时间更短(血糖>10.0 mmol/l时间:56.6% [1.2-100%] vs 78.0% [52.7-97.9%];p<0.001)。
  • 运动开始至最低点的血糖降幅EX60min vs EX120min更小(-3.8±2.7 vs -4.7±2.5 mmol/l;p<0.001)。
  • 两种运动时机的运动期间低血糖事件数量相似。
  • 超速效门冬胰岛素 vs 门冬胰岛素运动开始至最低点的血糖降幅更小(-4.1±2.3 vs -4.4±2.8 mmol/l;p=0.037)。
  • 运动期间低血糖事件数量相似,但超速效门冬胰岛素运动后低血糖更少(n=0,0% vs n=15,38%;p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The relationship between pre-meal insulin type, exercise timing and the risk of postprandial exercise-induced hypoglycaemia in people living with type 1 diabetes is unknown. We aimed to evaluate the effects of exercise timing (60 vs 120 min post meal) and different insulin types (aspart vs ultra-rapid aspart) on hypoglycaemic risk. METHODS: This was a four-way crossover randomised trial including 40 individuals with type 1 diabetes using multiple daily injections (mean HbA1c 56 mmol/mol [7.4%]). Participants, who were recruited from the Montreal Clinical Research Institute, undertook 60 min cycling sessions (60% of V ˙ O 2 peak ) after breakfast (60 min [EX60min] or 120 min [EX120min] post meal) with 50% of their usual insulin dose (aspart or ultra-rapid aspart). Eligibility criteria included age ≥18 years old, clinical diagnosis of type 1 diabetes for at least 1 year and HbA1c ≤80 mmol/mol (9.5%). Participants were allocated using sequentially numbered, opaque sealed envelopes. Participants were masked to their group assignment, and each participant was allocated a unique identification number to ensure anonymisation. The primary outcome was change in blood glucose levels between exercise onset and nadir. RESULTS: Prior to exercise onset, time spent in hyperglycaemia was lower for EX60min vs EX120min (time >10.0 mmol/l: 56.6% [1.2-100%] vs 78.0% [52.7-97.9%]; p<0.001). The glucose reduction between exercise onset and nadir was less pronounced with EX60min vs EX120min (-3.8±2.7 vs -4.7±2.5 mmol/l; p<0.001). A similar number of hypoglycaemic events occurred during both exercise timings. Blood glucose between exercise onset and nadir decreased less with ultra-rapid aspart compared with aspart (-4.1±2.3 vs -4.4±2.8 mmol/l; p=0.037). While a similar number of hypoglycaemic events during exercise were observed, less post-exercise hypoglycaemia occurred with ultra-rapid aspart (n=0, 0%, vs n=15, 38%; p=0.003). No interactions between insulin types and exercise timings were found. CONCLUSIONS/INTERPRETATION: EX60min blunted the pre-exercise glucose increase following breakfast and was associated with a smaller glucose reduction during exercise. Ultra-rapid aspart led to a smaller blood glucose reduction during exercise and might be associated with diminished post-exercise hypoglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov NCT03659799 FUNDING: This study was funded by Novo Nordisk Canada.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Molveau J, Myette-Côté É, Tagougui S, et al. Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial. Diabetologia. 2024. PMID: 39069599. doi:10.1007/s00125-024-06234-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。